The Phase II clinical trial for an all-oral treatment for #leishmaniasis has commenced in 🇪🇹 Ethiopia. The new molecule called LXE408, is expected to be safer than the current treatment.

We are grateful to all our partners for the support. Read more 👉bit.ly/3xJjzGo

Mierdon the 'mighty leishmaniasis rogue' & Melendi the 'Bishop of the dead rats'

In the most superficial part, the cytopathic effects of HSV-1 are perfectly observed. And as a surprise we can see Leishmania #Leishmania / #Leishmania sis #HSV1

The clinical trial in Ethiopia is financially supported by EDCTP, as part of the VL-INNO project, bringing together a wide range of partners to deliver more innovative diagnosis and treatment of #leishmaniasis . Learn about VL-INNO: bit.ly/4d9nkoM

The new molecule – LXE408 – is an oral pill 💊and expected to be safer than the current treatment. It has the potential to revolutionize treatment for the deeply neglected and hard-to-treat disease, as the Eastern Africa region charts the way to elimination. #leishmaniasis

Can a simple solution such as iron supplements help treat #leishmaniasis ? Initial study led by Sourav Banerjee shows that a bite by the vector, sandfly, can have systematic changes in iron levels and that iron supplementation can mitigate some of the effects!
Read more👇🏽 ASBMB

A top dog defense 🐶 😎
Presenting our expert on canine visceral leishmaniasis- Dr. Hianka Carvalho! During her time as a visiting scholar in our lab, she has done an amazing amount of work 👏. We’re proud of all that you’ve done and wish you all the best with your future 😊

I am happy to share our recent article 'A Case Series of Hemophagocytic Lymphohistiocytosis: An Atypical Presentation of Visceral Leishmaniasis' - Mark Grigoryan
YSMU Cureus

#Cancer #HLH #OncoDaily #Oncology #VisceralLeishmaniasis

oncodaily.com/52915.html

Iron supplements can be a crucial tool in managing the symptoms of leishmaniasis. Researchers are still working on how the infection impacts our iron levels, but, boosting iron intake can help combat this global health threat: asbmb.org/asbmb-today/sc… ANKITA ARORA ASBMB Journal of Biological Chemistry

📣 New #HopeForLeishmaniasis ! Together with our partners, we’ve started a Phase II clinical trial for a potential all-oral medicine to treat visceral #leishmaniasis at the University of Gondar in Ethiopia.

Read press release ➡️ bit.ly/3xJjzGo #beatNTDs 🧵

Local amphotericin B therapy for Cutaneous Leishmaniasis: A systematic review journals.plos.org/plosntds/artic…

why did I promise to help this babe review her master’s assignment o because what do I know about leishmaniasis? 😭🤡

⁦⁦⁦⁦UAMS Internal Medicine Residency⁩ ‘s own Dr. Ples Spradley making the diagnosis of Leishmaniasis at #IM2024 Thieves Market! ⁦ArkansasACP⁩ ⁦UAMS Infectious Diseases⁩ #IMProud

Visceral Leishmaniasis in 2 Patients Treated With Lenalidomide and Dexamethasone: A Possible Correlation With Blunted Immune Response journals.lww.com/hemasphere/ful…

Leishmaniasis is caused by a protozoan parasite
Transmitted by sandflies
Dermal histiocytes show cytoplasmic vacuoles containing a rim of tiny organisms, the Marquee sign.
✅Protozoa. Fungus is also acceptable since Histoplasma yeasts are about the same size as Leishmania

Great to be making progress with a new chemical entity: we’ve entered a Phase II clinical trial testing LXE408, a Novartis molecule, to treat visceral #leishmaniasis at the University of Gondar. This is an important step towards a potential, much-needed, all-oral treatment.

LXE408 was initially discovered by Novartis. DNDi and Novartis initiated a collaboration in 2020 to jointly develop LXE408. If trial results are positive and the new treatment is approved, Novartis has committed to distributing the drug on an affordable basis. #leishmaniasis

A Phase II clinical trial for a potential all-oral treatment for visceral #leishmaniasis has begun in Ethiopia at
the University of Gondar, conducted by Drugs for Neglected Diseases initiative and partners.

The new molecule is expected to be safer than the current treatment. bit.ly/3xJjzGo #beatNTDs

Good news for leishmaniasis, one of the neglected tropical diseases.The current 1 st line treatment is 17 day injections.Oral treatment will be a break through for our patients, relieving them from the painful injections. We look forward to a successful clinical trial.

Also known as #kalaazar , visceral #leishmaniasis is the world’s deadliest parasitic killer after malaria.

One billion people are at risk. Eastern Africa currently has the highest number of cases. #Climatechange could lead to visceral leishmaniasis expanding to other areas.